Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds

Blood ◽  
2001 ◽  
Vol 97 (1) ◽  
pp. 297-304 ◽  
Author(s):  
Alexander M. Cole ◽  
Jishu Shi ◽  
Alejandro Ceccarelli ◽  
Yong-Hwan Kim ◽  
Albert Park ◽  
...  

Abstract The host defense roles of neutrophil elastase in a porcine skin wound chamber model were explored. Analysis of wound fluid by acid-urea polyacrylamide gel electrophoresis, Western blot, and bacterial overlay confirmed that the neutrophil-derived protegrins constituted the major stable antimicrobial polypeptide in the wound fluid. The application to the wound of 0.10 and 0.25 mM N-methoxysuccinyl-alanine-alanine-proline-valine (AAPV) chloromethyl ketone, a specific neutrophil elastase inhibitor (NEI), blocked the proteolytic activation of protegrins and diminished the associated antimicrobial activity as detected by radial diffusion assay againstStaphylococcus epidermidis, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans or by bacterial gel overlay against S epidermidis and E coli. The application of the related cathepsin G inhibitor (CGI), benzyloxycarbonyl-glycine-leucine-phenylalanine (ZGLF) chloromethyl ketone, had no effect. In wound chambers that received 106 colony-forming unit (CFU)/mL of S epidermidis, the presence of NEI significantly decreased the 24-hour clearance of bacteria from the wound compared to wounds treated with CGI or solvent only. Neither inhibitor, at 0.10 or 0.25 mM concentration, affected leukocyte accumulation or degranulation in the wound chambers. The in vitro microbicidal decrement due to NEI was restored by an amount of the specific protegrin (PG-1), which was equivalent to the measured difference of protegrin between control and inhibited chambers. Administration of 1 μg/mL exogenous PG-1 4 hours after chamber preparation was sufficient to normalize in vivo antimicrobial activity. Although pharmacologic NEIs are promising candidates as anti-inflammatory drugs, they may impair host defense in part by inhibiting the activation of cathelicidins by neutrophil elastase.

1999 ◽  
Vol 66 (5) ◽  
pp. 501-508 ◽  
Author(s):  
F KOIZUMI ◽  
M MURAKAMI ◽  
H KAGEYAMA ◽  
M KATASHIMA ◽  
M TERAKAWA ◽  
...  

2017 ◽  
Vol 103 (6) ◽  
pp. 1781-1787 ◽  
Author(s):  
Mariko Fukui ◽  
Kazuya Takamochi ◽  
Shiaki Oh ◽  
Takeshi Matsunaga ◽  
Kazuhiro Suzuki ◽  
...  

2017 ◽  
Author(s):  
Hironori Mikumo ◽  
Toyoshi Yanagihara ◽  
Naoki Hamada ◽  
Eiji Harada ◽  
Saiko Ogata-Suetsugu ◽  
...  

ABSTRACTBackground and objectiveGefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is an effective therapeutic agent for non-small cell lung cancer with EGFR mutations. It can cause severe acute pneumonitis in some patients. We previously demonstrated that mice with naphthalene-induced airway epithelial injury developed severe gefitinib-induced pneumonitis and that neutrophils played important roles in the development of the disease. This study aimed to investigate the effects of the neutrophil elastase inhibitor sivelestat on gefitinib-induced pneumonitis in mice.MethodsC57BL/6J mice received naphthalene (200 mg/kg) intraperitoneally on day 0. Gefitinib (250 or 300 mg/kg) was orally administered to mice from day −1 until day 13. Sivelestat (150 mg/kg) was administered intraperitoneally from day 1 until day 13. Bronchoalveolar lavage fluid (BALF) and lung tissues were sampled on day 14.ResultsSivelestat treatment significantly reduced the protein level, neutrophil count, neutrophil elastase activity in BALF, and severity of histopathologic findings on day 14 for mice administered with 250 mg/kg of gefitinib. Moreover, sivelestat treatment significantly improved the survival of mice administered with 300 mg/kg of gefitinib. Conclusions: These results indicate that sivelestat is a promising therapeutic agent for severe acute pneumonitis caused by gefitinib.Summary statementNeutrophil elastase inhibitor sivelestat is a promising therapeutic agent for severe acute pneumonitis caused by gefitinib.


2002 ◽  
Vol 26 (3) ◽  
pp. 290-297 ◽  
Author(s):  
Christophe Delacourt ◽  
Sabine Hérigault ◽  
Christophe Delclaux ◽  
Alain Poncin ◽  
Micheline Levame ◽  
...  

2003 ◽  
Vol 76 (4) ◽  
pp. 1234-1239 ◽  
Author(s):  
Yukihiro Yoshimura ◽  
Yuji Hiramatsu ◽  
Yukio Sato ◽  
Satoshi Homma ◽  
Yoshiharu Enomoto ◽  
...  

2015 ◽  
Vol 63 (12) ◽  
pp. 645-651 ◽  
Author(s):  
Masaaki Harada ◽  
Takahiro Oto ◽  
Shinji Otani ◽  
Kentaroh Miyoshi ◽  
Masanori Okada ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document